Rehab of NAD(P)-dependent enzymes with NAD(P)-based inhibitors

Current Medicinal Chemistry

Volumn 18, Issue 13, 2011, Pages 1891-1908

  Felczak, K ^a   Pankiewicz, K W ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Conformational restrictions; IMPDH; Inhibitor design; NAD(P) analogues

Indexed keywords

AG 18051; AVN 944; C2 MAD; ENZYME INHIBITOR; MERIMEPODIB; MIZORIBINE; MYCOPHENOLIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXIDOREDUCTASE INHIBITOR; RIBAVIRIN; TIAZOFURIN; UNCLASSIFIED DRUG; VX 944;

ARTICLE; BINDING SITE; DRUG POTENCY; DRUG SELECTIVITY; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; NONHUMAN;

ANIMALS; ENZYME INHIBITORS; ENZYMES; HUMANS; NAD; NADP; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY;

EID: 79957943043     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711795590066     Document Type: Article

References (92)

1. Herken, H. Antimetabolic action of 6-aminonicotinamide on pentose pathway in the brain. McMillan: London, 1971.
2. Li, H.; Hallows, W.H.; Punzi, J.S.; Pankiewicz, K.W.; Watanabe, K.A.; Goldstein, B.M., Crystallographic studies of isosteric NAD analogues bound to alcohol dehydrogenase: specificity and substrate binding in two ternary complexes. Biochemistry, 1994, 33(39), 11734-11744. (Pubitemid 24327981)
3. Gebeyehu, G.; Marquez, V.E.; Van Cott, A.; Cooney, D.A.; Kelley, J.A.; Jayaram, H.N.; Ahluwalia, G.S.; Dion, R.L.; Wilson, Y.A.; Johns, D.G. Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase. J. Med. Chem., 1985, 28(1), 99-105. (Pubitemid 15156302)
4. Chen, L.; Petrelli, R.; Gao, G.; Bonnac, L.; Yu, J.S.; Bennett, E.M.; Pankiewicz, K.W. Nicotinamide adenine dinucleotide based therapeutics. Curr. Med. Chem., 2008, 15, 650-670. (Pubitemid 351516802)
5. Braun-Sand, S.B.; Peetz, M. Inosine monophosphate dehydrogenase as a target for antiviral, anticancer, antimicrobial and immunosuppressive therapeutics. Future Med. Chem., 2010, 2(1), 81-92.
6. Khan, J.A.; Forouhar, F.; Tao, X.; Tong, L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin. Ther. Targets, 2007, 11(5), 695-705. (Pubitemid 46730083)
7. Cholewinski, G.; Malachowska-Ugarte, M.; Dzierzbicka, K. The chemistry of mycophenolic acid-synthesis and modifications towards desired biological activity. Curr. Med. Chem., 2010, 17(18), 1926-1941.
8. Pankiewicz, K.W.; Goldstein, B.M. Eds. Inosine Monophosphate Dehydrogenase: A Major Therapeutic Target. Oxford University Press: Washinghton, 2003.
9. Hedstrom, L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem. Rev., 2009, 109(7), 2903-2928.
10. Natsumeda, Y.; Ohno, S.; Kawasaki, H.; Konno, Y.; Weber, G.; Suzuki, K. Two distinct cDNAs for human IMP dehydrogenase. J. Biol. Chem., 1990, 265(9), 5292-5295.
11. Collart, F.R.; Huberman, E., Cloning and sequence analysis of the human and Chinese hamster inosine-5'-monophosphate dehydrogenase cDNAs. J. Biol. Chem., 1988, 263(30), 15769-15772.
12. Hager, P.W.; Collart, F.R.; Huberman, E.; Mitchell, B.S. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem. Pharmacol., 1995, 49(9), 1323-1329.
13. Chong, C.R.; Qian, D.Z.; Pan, F.; Wei, Y.; Pili, R.; Sullivan, D.J. Jr.; Liu, J.O. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J. Med. Chem., 2006, 49(9), 2677-2680.
14. Collart, F.R.; Chubb, C.B.; Mirkin, B.L.; Huberman, E. Increased inosine-5'- phosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines. Cancer Res., 1992, 52(20), 5826-5828.
15. Balzarini, J.; De Clercq, E. Assay method for monitoring the inhibitory effects of antimetabolites on the activity of inosinate dehydrogenase in intact human CEM lymphocytes. Biochem. J., 1992, 287 (Pt 3), 785-790.
16. Grifantini, M. Tiazofurine ICN Pharmaceuticals. Curr. Opin. Investig. Drugs, 2000, 1(2), 257-262.
17. Bottoms, C.A.; Smith, P.E.; Tanner, J.J. A structurally conserved water molecule in Rossmann dinucleotide-binding domains. Protein Sci., 2002, 11(9), 2125-2137. (Pubitemid 34919616)
18. Poncet-Montange, G.; Assairi, L.; Arold, S.; Pochet, S.; Labesse, G. NAD kinases use substrate-assisted catalysis for specific recognition of NAD. J. Biol. Chem., 2007, 282, 33925-33934. (Pubitemid 350159448)
19. Petrelli, R.; Sham, Y.Y.; Chen, L.; Felczak, K.; Bennett, E.; Wilson, D.; Aldrich, C.; Yu, J.S.; Cappellacci, L.; Franchetti, P.; Grifantini, M.; Mazzola, F.; Di Stefano, M.; Magni, G.; Pankiewicz, K.W. Selective inhibition of nicotinamide adenine dinucleotide kinases by dinucleoside disulfide mimics of nicotinamide adenine dinucleotide analogues. Bioorg. Med. Chem., 2009, 17(15), 5656-5664.
20. Khan, A. R.; Parrish, J.C.; Fraser, M.E.; Smith, W.W.; Bartlett, P.A.; James, M.N.G. Lowering the entropic barrier for binding conformationally flexible inhibitors to enzymes. Biochemistry, 1998, 37, 16839-16845. (Pubitemid 28566760)
21. Westheimer, F.N. In Pyridine nucleotide coenzymes: chemical, biochemical, and medical aspects. Dolphin, D.; Avramovic, O.; Poulson, R., Eds.; Wiley, 1987; Vol. Part A, pp. 255-321.
22. Oppenheimer, N.J. The stereospecificity of oxidation of alpha-[4R- 2H]NADH by dehydrogenases. J. Biol. Chem., 1986, 261(26), 12209-12212. (Pubitemid 17202785)
23. Goldstein, B.M.; Li, H.; Hallows, W.H.; Langs, D.A.; Franchetti, P.; Cappellacci, L.; Grifantini, M. C-glycosyl bond conformation in oxazofurin: crystallographic and computational studies of the oxazole analogue of tiazofurin. J. Med. Chem., 1994, 37(11), 1684-1688. (Pubitemid 24195483)
24. Franchetti, P.; Cappellacci, L.; Perlini, P.; Jayaram, H.N.; Butler, A.; Schneider, B.P.; Collart, F.R.; Huberman, E.; Grifantini, M. Isosteric analogues of nicotinamide adenine dinucleotide derived from furanfurin, thiophenfurin, and selenophenfurin as mammalian inosine monophosphate dehydrogenase (type I and II) inhibitors. J. Med. Chem., 1998, 41(10), 1702-1707. (Pubitemid 28221964)
25. Tavale, S.S.; Sobell, H.M. Crystal and molecular structure of 8- bromoguanosine and 8-bromoadenosine, two purine nucleosides in the syn conformation. J. Mol. Biol., 1970, 48(1), 109-123.
26. Hockova, D.; Holy, A., Synthesis of some "abbreviated" NAD(+) analogues. Collection Czechoslovak Chem. Commun., 1997, 62(6), 948-956.
27. Hockova, D.; Votavowa, H.; Holy, A. Synthesis and chiroptical properties of some abbreviated NAD analogues. Tetrahedron Assymetry, 1995, 6, 2375-2384.
28. Migaud, M.E.; Pederick, R.L.; Bailey, V.C.; Potter, B.V. Probing Aplysia californica adenosine 5'-diphosphate ribosyl cyclase for substrate binding requirements: design of potent inhibitors. Biochemistry, 1999, 38(28), 9105-9114.
29. Zhang, B.; Wagner, G.K.; Weber, K.; Garnham, C.; Morgan, A.J.; Galione, A.; Guse, A.H.; Potter, B.V. 2'-deoxy cyclic adenosine 5'-diphosphate ribose derivatives: importance of the 2'-hydroxyl motif for the antagonistic activity of 8-substituted cADPR derivatives. J. Med. Chem., 2008, 51(6), 1623-1636. (Pubitemid 351438846)
30. Shuto, S.; Fukuoka, M.; Manikowsky, A.; Ueno, Y.; Nakano, T.; Kuroda, R.; Kuroda, H.; Matsuda, A. Total synthesis of cyclic ADP-carbocyclic-ribose, a stable mimic of Ca2+-mobilizing second messenger cyclic ADP-ribose. J. Am. Chem. Soc., 2001, 123(36), 8750-8759. (Pubitemid 32852675)
31. Cen, Y.; Sauve, A.A. Diastereocontrolled electrophilic fluorinations of 2- deoxyribonolactone: syntheses of all corresponding 2-deoxy-2-fluorolactones and 2'-deoxy-2'-fluoro-NAD+s. J. Org. Chem., 2009, 74(16), 5779-5789.
32. Sauve, A.A.; Schramm, V.L. Mechanism-based inhibitors of CD38: a mammalian cyclic ADP-ribose synthetase. Biochemistry, 2002, 41(26), 8455-8463. (Pubitemid 34705500)
33. Pankiewicz, K.W.; Krzeminski, J.; Ciszewski, L.A.; Ren, W.Y.; Watanabe, K.A. A Synthesis of 9-(2-Deoxy-2-fluoro-D- arabinofuranosyl)adenine and Hypoxanthine. An Effect of C3-Endo to C2- -Endo Conformational Shift on the Reaction Course of 2-Hydroxyl Group with DAST. J. Org. Chem., 1992, 57, 553-559.
34. Bonnac, L.; Chen, L.; Pathak, R.; Gao, G.; Ming, Q.; Bennett, E.; Felczak, K.; Kullberg, M.; Patterson, S.E.; Mazzola, F.; Magni, G.; Pankiewicz, K.W. Probing binding requirements of NAD kinase with modified substrate (NAD) analogues. Bioorg. Med. Chem. Lett., 2007, 17(6), 1512-1515. (Pubitemid 46274365)
35. Zatorski, A.; Goldstein, B.M.; Colby, T.D.; Jones, J.P.; Pankiewicz, K.W., Potent inhibitors of human inosine monophosphate dehydrogenase type II. Fluorine-substituted analogues of thiazole-4-carboxamide adenine dinucleotide. J. Med. Chem., 1995, 38(7), 1098-1105.
36. Rawat, R.; Whitty, A.; Tonge, P.J., The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc. Natl. Acad. Sci. USA, 2003, 100(24), 13881-13886. (Pubitemid 37499160)
37. Rozwarski, D.A.; Grant, G.A.; Barton, D.H.; Jacobs, W.R. Jr.; Sacchettini, J.C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science, 1998, 279(5347), 98-102. (Pubitemid 28079164)
38. Lei, B.; Wei, C.J.; Tu, S.C. Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor. J. Biol. Chem., 2000, 275(4), 2520-2526. (Pubitemid 30082015)
39. Basso, L.A.; Zheng, R.; Musser, J.M.; Jacobs, W.R., Jr.; Blanchard, J.S. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazidresistant clinical isolates. J. Infect. Dis., 1998, 178(3), 769-775. (Pubitemid 28397225)
40. Ducasse-Cabanot, S.; Cohen-Gonsaud, M.; Marrakchi, H.; Nguyen, M.; Zerbib, D.; Bernadou, J.; Daffe, M.; Labesse, G.; Quemard, A. In vitro inhibition of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA by isoniazid. Antimicrob. Agents Chemother., 2004, 48(1), 242-249. (Pubitemid 38040204)
41. Nguyen, M.; Claparols, C.; Bernadou, J.; Meunier, B. A fast and efficient metal-mediated oxidation of isoniazid and identification of isoniazid- NAD(H) adducts. Chembiochem, 2001, 2(12), 877-883. (Pubitemid 33722701)
42. Nguyen, M.; Quemard, A.; Broussy, S.; Bernadou, J.; Meunier, B. Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2002, 46(7), 2137-2144. (Pubitemid 34665908)
43. Broussy, S.; Coppel, Y.; Nguyen, M.; Bernadou, J.; Meunier, B. 1H and 13C NMR characterization of hemiamidal isoniazid-NAD(H) adducts as possible inhibitors of InhA reductase of Mycobacterium tuberculosis. Chemistry, 2003, 9(9), 2034-2038.
44. Broussy, S.; Bernardes-Genisson, V.; Quemard, A.; Meunier, B.; Bernadou, J. The first chemical synthesis of the core structure of the benzoylhydrazine- NAD adduct, a competitive inhibitor of the Mycobacterium tuberculosis enoyl reductase. J. Org. Chem., 2005, 70(25), 10502-10510. (Pubitemid 41759924)
45. Delaine, T.; Bernardes-Genisson, V.; Meunier, B.; Bernadou, J., Synthesis of the isonicotinoylnicotinamide scaffolds of the naturally occurring isoniazid- NAD(P) adducts. J. Org. Chem., 2007, 72(2), 675-678. (Pubitemid 46106539)
46. Delaine, T.; Bernardes-Genisson, V.; Quemard, A.; Constant, P.; Meunier, B.; Bernadou, J. Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents. Eur. J. Med. Chem., 2010, 45(10), 4554-4561.
47. Zatorski, A.; Watanabe, K.A.; Carr, S.F.; Goldstein, B.M.; Pankiewicz, K.W. Chemical synthesis of benzamide adenine dinucleotide: inhibition of inosine monophosphate dehydrogenase (types I and II). J. Med. Chem., 1996, 39(12), 2422-2426. (Pubitemid 26191132)
48. Bonnac, L.; Gao, G.Y.; Chen, L.; Felczak, K.; Bennett, E.M.; Xu, H.; Kim, T.; Liu, N.; Oh, H.; Tonge, P.J.; Pankiewicz, K.W. Synthesis of 4- phenoxybenzamide adenine dinucleotide as NAD analogue with inhibitory activity against enoyl-ACP reductase (InhA) of Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett., 2007, 17(16), 4588-4591. (Pubitemid 47058941)
49. Pankiewicz, K.W.; Lesiak, K.; Zatorski, A.; Goldstein, B.M.; Carr, S.F.; Sochacki, M.; Majumdar, A.; Seidman, M.; Watanabe, K.A. The practical synthesis of a methylenebisphosphonate analogue of benzamide adenine dinucleotide: inhibition of human inosine monophosphate dehydrogenase (type I and II). J. Med. Chem., 1997, 40(8), 1287-1291. (Pubitemid 27175108)
50. Bossi, R.T.; Aliverti, A.; Raimondi, D.; Fischer, F.; Zanetti, G.; Ferrari, D.; Tahallah, N.; Maier, C.S.; Heck, A.J.; Rizzi, M.; Mattevi, A. A covalent modification of NADP+ revealed by the atomic resolution structure of FprA, a Mycobacterium tuberculosis oxidoreductase. Biochemistry, 2002, 41(28), 8807-8818. (Pubitemid 34774394)
51. Dutta, S.P.; Crain, P.F.; McCloskey, J.A.; Chheda, G.B. Isolation and characterization of 1-beta-D-ribofuranosylpyridin-4-one-3-carboxamide from human urine. Life Sci., 1979, 24(15), 1381-1388. (Pubitemid 9164691)
52. Slominska, E.M.; Carrey, E.A.; Foks, H.; Orlewska, C.; Wieczerzak, E.; Sowinski, P.; Yacoub, M.H.; Marinaki, A.M.; Simmonds, H.A.; Smolenski, R.T. A novel nucleotide found in human erythrocytes, 4-pyridone-3- carboxamide-1-beta- D-ribonucleoside triphosphate. J. Biol. Chem., 2006, 281(43), 32057-32064. (Pubitemid 46036759)
53. Sulzenbacher, G.; Alvarez, K.; Van Den Heuvel, R.H.; Versluis, C.; Spinelli, S.; Campanacci, V.; Valencia, C.; Cambillau, C.; Eklund, H.; Tegoni, M., Crystal structure of E.coli alcohol dehydrogenase YqhD: evidence of a covalently modified NADP coenzyme. J. Mol. Biol., 2004, 342(2), 489-502. (Pubitemid 39149753)
54. Benach, J.; Atrian, S.; Gonzalez-Duarte, R.; Ladenstein, R., The catalytic reaction and inhibition mechanism of Drosophila alcohol dehydrogenase: observation of an enzyme-bound NAD-ketone adduct at 1.4 A resolution by X-ray crystallography. J. Mol. Biol., 1999, 289(2), 335-355. (Pubitemid 29278386)
55. Striepen, B.; Pruijssers, A.J.; Huang, J.; Li, C.; Gubbels, M.J.; Umejiego, N.N.; Hedstrom, L.; Kissinger, J.C. Gene transfer in the evolution of parasite nucleotide biosynthesis. Proc. Natl. Acad. Sci. USA, 2004.
56. Granchi, C.; Bertini, S.; Macchia, M.; Minutolo, F. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr. Med. Chem., 2010, 17(7), 672-697.
57. Albert, J.M.; Cao, C.; Kim, K.W.; Willey, C.D.; Geng, L.; Xiao, D.; Wang, H.; Sandler, A.; Johnson, D.H.; Colevas, A.D.; Low, J.; Rothenberg, M.L.; Lu, B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res., 2007, 13(10), 3033-3042. (Pubitemid 46849580)
58. Bentley, R. Mycophenolic Acid: a one hundred year odyssey from antibiotic to immunosuppressant. Chem. Rev., 2000, 100(10), 3801-3826.
59. Sintchak, M.D.; Fleming, M.A.; Futer, O.; Raybuck, S.A.; Chambers, S.P.; Caron, P.R.; Murcko, M.A.; Wilson, K.P. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell, 1996, 85(6), 921-930. (Pubitemid 26192142)
60. Pankiewicz, K.W.; Lesiak-Watanabe, K.B.; Watanabe, K.A.; Patterson, S.E.; Jayaram, H.N.; Yalowitz, J.A.; Miller, M.D.; Seidman, M.; Majumdar, A.; Prehna, G.; Goldstein, B.M., Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia. J. Med. Chem., 2002, 45(3), 703-712. (Pubitemid 34145717)
61. Chen, L.; Gao, G.; Felczak, K.; Bonnac, L.; Patterson, S.E.; Wilson, D.; Bennett, E.M.; Jayaram, H.N.; Hedstrom, L.; Pankiewicz, K.W. Probing Binding Requirements of Type I and Type II Isoforms of Inosine Monophosphate Dehydrogenase with Adenine-Modified Nicotinamide Adenine Dinucleotide Analogues. J. Med. Chem., 2007, 50(23), 5743-5751. (Pubitemid 350106029)
62. Sintchak, M.D.; Nimmesgern, E. The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology, 2000, 47(2-3), 163-184. (Pubitemid 30394537)
63. Iwanowicz, E.J.; Watterson, S.H.; Liu, C.; Gu, H.H.; Mitt, T.; Leftheris, K.; Barrish, J.C.; Fleener, C.A.; Rouleau, K.; Sherbina, N.Z.; Hollenbaugh, D.L. Novel guanidine-based inhibitors of inosine monophosphate dehydrogenase. Bioorg. Med. Chem. Lett., 2002, 12(20), 2931-2934. (Pubitemid 35266762)
64. Dhar, T.G.; Shen, Z.; Gu, H.H.; Chen, P.; Norris, D.; Watterson, S.H.; Ballentine, S.K.; Fleener, C.A.; Rouleau, K.A.; Barrish, J.C.; Townsend, R.; Hollenbaugh, D.L.; Iwanowicz, E.J. 3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structureactivity relationships. Bioorg. Med. Chem. Lett., 2003, 13(20), 3557-3560. (Pubitemid 37141429)
65. Pickett, S.D.; Sherborne, B.S.; Wilkinson, T.; Bennett, J.; Borkakoti, N.; Broadhurst, M.; Hurst, D.; Kilford, I.; McKinnell, M.; Jones, P.S. Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. Bioorg. Med. Chem. Lett., 2003, 13(10), 1691-1694. (Pubitemid 36561143)
66. Watkins, W.J.; Chen, J.M.; Cho, A.; Chong, L.; Collins, N.; Fardis, M.; Huang, W.; Hung, M.; Kirschberg, T.; Lee, W.A.; Liu, X.; Thomas, W.; Xu, J.; Zeynalzadegan, A.; Zhang, J., Phosphonic acid-containing analogues ofmycophenolic acid as inhibitors of IMPDH. Bioorg. Med. Chem. Lett., 2006, 16(13), 3479-3483. (Pubitemid 43777107)
67. Buckley, G.M.; Davies, N.; Dyke, H.J.; Gilbert, P.J.; Hannah, D.R.; Haughan, A.F.; Hunt, C.A.; Pitt, W.R.; Profit, R.H.; Ray, N.C.; Richard, M.D.; Sharpe, A.; Taylor, A.J.; Whitworth, J.M.; Williams, S.C. Quinazolinethiones and quinazolinediones, novel inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationships. Bioorg. Med. Chem. Lett., 2005, 15(3), 751-754. (Pubitemid 40143160)
68. Birch, H.L.; Buckley, G.M.; Davies, N.; Dyke, H.J.; Frost, E.J.; Gilbert, P.J.; Hannah, D.R.; Haughan, A.F.; Madigan, M.J.; Morgan, T.; Pitt, W.R.; Ratcliffe, A.J.; Ray, N.C.; Richard, M.D.; Sharpe, A.; Taylor, A.J.; Whitworth, J.M.; Williams, S.C. Novel 7-methoxy-6-oxazol-5-yl-2,3- dihydro-1H-quinazolin-4- ones as IMPDH inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(23), 5335-5339. (Pubitemid 41463676)
69. Hamilton, J.M.; Harding, M.W.; Genna, T.; Bol, D.K. A phase I doseranging study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of AVN944, an IMPDH inhibitor, in healthy male volunteers. J. Clin. Pharmacol., 2009, 49(1), 30-38.
70. Floryk, D.; Thompson, T.C. Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells. Int. J. Cancer, 2008, 123(10), 2294-2302.
71. Krasovski, A.; Knochel, P. A LiCl-Mediated Br/Mg Exchange Reaction for the Preparation of Functionalized Aryl- and Heteroarylmagnesium Compounds from Organic Bromides. Angew. Chem. Int. Ed., 2004, 43, 3333-3336. (Pubitemid 39257594)
72. Pope, S.A.; Burtin, G.E.; Clayton, P.T.; Madge, D.J.; Muller, D.P. Synthesis and analysis of conjugates of the major vitamin E metabolite, alpha-CEHC. Free Radic. Biol. Med., 2002, 15, 807-817. (Pubitemid 35232315)
73. Guillen Schlippe, Y.V.; Hedstrom, L. Guanidine derivatives rescue the Arg418Ala mutation of Tritrichomonas foetus IMP dehydrogenase. Biochemistry, 2005, 44(50), 16695-16700. (Pubitemid 41832049)
74. Gollapalli, D.R.; Macpherson, I.S.; Liechti, G.; Gorla, S.K.; Goldberg, J.B.; Hedstrom, L. Structural determinants of inhibitor selectivity in prokaryotic IMP dehydrogenases. Chem. Biol., 2010, 17(10), 1084-1091.
75. Kennedy, K.J.; Bressi, J.C.; Gelb, M.H. A disubstituted NAD+ analogue is a nanomolar inhibitor of trypanosomal glyceraldehyde-3-phosphate dehydrogenase. Bioorg. Med. Chem. Lett., 2001, 11(2), 95-98. (Pubitemid 32101441)
76. Natsumeda, Y.; Carr, S.F. Human type I and II IMP dehydrogenases as drug targets. Ann. N. Y. Acad. Sci., 1993, 696, 88-93. (Pubitemid 24062780)
77. Carr, S.F.; Papp, E.; Wu, J.C.; Natsumeda, Y. Characterization of human type I and type II IMP dehydrogenases. J. Biol. Chem., 1993, 268(36), 27286-27290. (Pubitemid 24006448)
78. Alland, D.; Steyn, A.J.; Weisbrod, T.; Aldrich, K.; Jacobs, W.R. Jr. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J. Bacteriol., 2000, 182(7), 1802-1811. (Pubitemid 30165365)
79. Anderson, R.M.; Bitterman, K.J.; Wood, J.G.; Medvedik, O.; Sinclair, D.A. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature, 2003, 423(6936), 181-185. (Pubitemid 36569542)
80. Colby, T.D.; Vanderveen, K.; Strickler, M.D.; Markham, G.D.; Goldstein, B.M. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc. Natl. Acad. Sci. USA, 1999, 96(7), 3531-3536. (Pubitemid 29168943)
81. An, X.; Tiwari, A.K.; Sun, Y.; Ding, P.R.; Ashby, C.R. Jr.; Chen, Z.S. BCRABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk. Res., 2010, 34(10), 1255-1268.
82. Liao, J.J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem., 2007, 50(3), 409-424. (Pubitemid 46239775)
83. Pankiewicz, K.; Goldstein, B. In Inosine Monophosphate Dehydrogenase; A Major Therapeutic Target. Pankiewicz, K., Goldstein, B.M., Ed.; Oxford University Press: Washington, 2003; Vol. 839, pp. 1-20.
84. Favus, M.J. Bisphosphonates for osteoporosis. N. Engl. J. Med., 2010, 363(21), 2027-2035.
85. Sun, M.; Iqbal, J.; Singh, S.; Sun, L.; Zaidi, M. The crossover of bisphosphonates to cancer therapy. Ann. N. Y. Acad. Sci., 2010, 1211, 107-112.
86. Berry, S.; Waldron, T.; Winquist, E.; Lukka, H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Can. J. Urol., 2006, 13(4), 3180-3188.
87. Lawson, M.A.; Ashcroft, J.; Croucher, P.I. Bisphosphonate therapy in the treatment of multiple myeloma. Curr. Pharm. Des., 2010, 16(27), 3028-3036.
88. Ghosh, S.; Chan, J.M.; Lea, C.R.; Meints, G.A.; Lewis, J.C.; Tovian, Z.S.; Flessner, R.M.; Loftus, T.C.; Bruchhaus, I.; Kendrick, H.; Croft, S.L.; Kemp, R.G.; Kobayashi, S.; Nozaki, T.; Oldfield, E. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J. Med. Chem., 2004, 47(1), 175-187. (Pubitemid 38040501)
89. Felczak, K.; Chen, L.; Wilson, D.; Williams, J.; Vince, R.; Petrelli, R.; Jayaram, H.N.; Kusumanchi, P.; Kumar, M.; Pankiewicz, K.W. Cofactor type inhibitors of inosine monophosphate dehydrogenase via modular approach: Targeting the pyrophosphate binding sub-domain. Bioorg. Med. Chem., 2011, 19, 1594-1605.
90. Rejman, D.; Olesiak, M.; Chen, L.; Patterson, S.E.; Wilson, D.; Jayaram, H.N.; Hedstrom, L.; Pankiewicz, K.W. Novel methylenephosphophosphonate analogues of mycophenolic adenine dinucleotide. Inhibition of inosine monophosphate dehydrogenase. J. Med. Chem., 2006, 49(16), 5018-5022. (Pubitemid 44201060)
91. Chen, L.; Gao, G.; Bonnac, L.; Wilson, D.J.; Bennett, E.M.; Jayaram, H.N.; Pankiewicz, K.W. Methylenebis(sulfonamide) linked nicotinamide adenine dinucleotide analogue as an inosine monophosphate dehydrogenase inhibitor. Bioorg. Med. Chem. Lett., 2007, 17(11), 3152-3155. (Pubitemid 46702619)
92. Chen, L.; Wilson, D.J.; Xu, Y.; Aldrich, C.C.; Felczak, K.; Sham, Y.Y.; Pankiewicz, K.W. Triazole-linked inhibitors of inosine monophosphate dehydrogenase from human and Mycobacterium tuberculosis. J. Med. Chem., 2010, 53(12), 4768-4778.